Utilizing Alvotech/Teva’s ustekinumab biosimilar, Navitus Health will begin offering its Lumicera Health-branded ustekinumab-aekn, beginning July 1, while excluding the reference product Stelara. The net price of this product is said to be approximately $1,000 per 90-mg dose, or more than a 90% discount from Stelara’s wholesale acquisition cost (WAC).
Like the big 3 PBMs with private-label biosimilar access, Navitus is using its a wholly owned specialty pharmacy subsidiary (Lumicera) to distribute its version of Selarsdi. For Navitus clients who do not employ Lumicera as their specialty pharmacy, the PBM will also cover the Biocon’s Yesintek and Celltrion’s Steqeyma biosimilars. Navitus did indicate though that this private label version will be available to other pharmacies.
Navitus estimates, in its 2024 Drug Trend Report, that the move to its private-label ustekinumab biosimilar will save its commercial clients $3.00 per member per month compared with the reference product.
